You just read:

Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

News provided by

Pliant Therapeutics, Inc.

Nov 20, 2018, 08:00 ET